Cell MedX Corp. (CMXC)
- Previous Close
0.0480 - Open
0.0480 - Bid --
- Ask --
- Day's Range
0.0470 - 0.0480 - 52 Week Range
0.0002 - 0.9312 - Volume
30,520 - Avg. Volume
13,931 - Market Cap (intraday)
14.267M - Beta (5Y Monthly) 32.83
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Cell MedX Corp., a biotech company, discovers, develops, and commercializes therapeutic and non-therapeutic products for patients with diabetes, Parkinson's disease, high blood pressure, neuropathy, and kidney functions. It develops and manufactures eBalance Pro System for professional use by healthcare practitioners in a clinical setting; and eBalance Home System for home use for general wellness and pain management treatment, which are controlled by the eBalance Console that acts as the central controller for three pre-programmed microcurrent algorithms, including wellness, pain management, and dual. The company also develops eBalance Home and eBalance Pro System for temporary relief of shoulder, waist, back, neck, arms, and legs. The company was formerly known as Sports Asylum, Inc. and changed its name to Cell MedX Corp. in September 2014. Cell MedX Corp. was incorporated in 2010 and is headquartered in Carson City, Nevada.
cellmedx.comRecent News: CMXC
Performance Overview: CMXC
Trailing total returns as of 4/18/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CMXC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CMXC
Valuation Measures
Market Cap
14.27M
Enterprise Value
14.51M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
66.33k
Price/Book (mrq)
--
Enterprise Value/Revenue
196.08k
Enterprise Value/EBITDA
-506.50
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-282.01%
Return on Equity (ttm)
--
Revenue (ttm)
74
Net Income Avi to Common (ttm)
-96.91k
Diluted EPS (ttm)
-0.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
79.68k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-1.14M